LYR-220
Chronic Rhinosinusitis (CRS)
Phase 2 (Inferred)In pipeline; for patients with polyps or prior surgery
Key Facts
Indication
Chronic Rhinosinusitis (CRS)
Phase
Phase 2 (Inferred)
Status
In pipeline; for patients with polyps or prior surgery
Company
About Lyra Therapeutics
Lyra Therapeutics is a clinical-stage biotechnology company with a singular mission: to transform the treatment of chronic rhinosinusitis (CRS) through targeted, long-acting local therapies. The company's core achievement is the development of a proprietary drug-eluting nasal mesh platform, which has advanced its lead candidate, LYR-210, into Phase 3 clinical trials. Lyra's strategy is to address the significant unmet need in the underserved CRS market by providing a durable, procedure-based solution that overcomes the limitations of current systemic and topical treatments. Success hinges on the clinical and regulatory success of LYR-210, which represents the company's primary near-term value driver.
View full company profileTherapeutic Areas
Other Chronic Rhinosinusitis (CRS) Drugs
| Drug | Company | Phase |
|---|---|---|
| LYR-210 | Lyra Therapeutics | Phase 3 |
| Airiver Drug Coated Balloon | Airiver Medical | Pivotal |